+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Proton pump inhibitor after endoscopic resection for esophageal squamous cell cancer: multicenter prospective randomized controlled trial



Proton pump inhibitor after endoscopic resection for esophageal squamous cell cancer: multicenter prospective randomized controlled trial



Journal of Gastroenterology 51(2): 104-111



Whether proton pump inhibitors (PPIs) relieve heartburn or precordial pain after endoscopic resection (ER) for esophageal squamous cell carcinoma (ESCC) remains unclear. The aim of this study was to investigate the efficacy of PPI therapy for these symptoms after ER for ESCC. We conducted a multicenter prospective randomized controlled trial among 15 hospitals in Japan. In total, 229 patients with cT1a ESCC were randomly assigned to receive PPI therapy for 5 weeks after ER (the PPI group, n = 115) or follow-up without PPI therapy (the non-PPI group, n = 114). The primary end point was the incidence of gastroesophageal reflux disease (GERD)-like symptoms after ER from a self-reported questionnaire (Frequency Scale for Symptoms of GERD). Secondary end points were ulcer healing rate at 5 weeks, incidence of pain, improvement rate of symptoms in those who started PPI therapy because of GERD-like symptoms in the non-PPI group, and adverse events. No significant difference was observed in the incidence of GERD-like symptoms after ER between the non-PPI and PPI groups (30 % vs 34 %, respectively). No significant differences were observed in the ulcer healing rate at 5 weeks (84 % vs 85 %) and incidence of pain within 1 week (36 % vs 45 %). In nine of ten patients (90 %) who started PPI therapy because of GERD-like symptoms in the non-PPI group, PPI administration relieved GERD-like symptoms. No adverse events related to PPI administration were observed. PPI therapy is not efficacious in reducing symptoms and did not promote healing of ulcers in patients undergoing ER for ESCC.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058654578

Download citation: RISBibTeXText

PMID: 25940151

DOI: 10.1007/s00535-015-1085-9


Related references

Effect of a proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer: a prospective randomized controlled trial. American Journal of Gastroenterology 102(8): 1610-1616, 2007

Proton pump inhibitor dose-related healing rate of artificial ulcers after endoscopic submucosal dissection: a prospective randomized controlled trial. Digestion 84(1): 46-53, 2011

T2062 Comparison of Healing Rate of Artificial Ulcer After Endoscopic Submucosal Dissection in Relation to the Dose of Proton Pump Inhibitor. a Prospective Randomized Controlled Trial. Gastroenterology 134(4): A-611, 2008

Sa1635 Comparison of Continuous Infusion and Bolus Injection of Proton Pump Inhibitor (Pantoprazole) for the Prevention of Bleeding After Endoscopic Submucosal Dissection: a Prospective Randomized Controlled Trial. Gastrointestinal Endoscopy 79(5): Ab282-Ab283, 2014

Comparison of manual and mechanical cervical esophagogastric anastomosis after esophageal resection for squamous cell carcinoma: a prospective randomized controlled trial. European Journal of Cardio-Thoracic Surgery 25(6): 1097-1101, 2004

Rebamipide plus proton pump inhibitor versus proton pump inhibitor alone in the treatment of endoscopic submucosal dissection-induced gastric ulcer: a meta-analysis of randomized controlled trials. Medicine 93(12): E64, 2014

Retraction. Rebamipide plus proton pump inhibitor versus proton pump inhibitor alone in treatment of endoscopic submucosal dissection-induced gastric ulcer: a meta-analysis of randomized controlled trials. Medicine 93(29): 399-399, 2015

Adjuvant radiotherapy, chemotherapy or surgery alone for high-risk histological node negative esophageal squamous cell carcinoma: Protocol for a multicenter prospective randomized controlled trial. Thoracic Cancer 9(12): 1801-1806, 2018

Can rebamipide and proton pump inhibitor combination therapy promote the healing of endoscopic submucosal dissection-induced ulcers? A randomized, prospective, multicenter study. Gastrointestinal Endoscopy 75(4): 739-747, 2012

Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial. Helicobacter 23(2): E12456, 2017

Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: early results from the Chinese University Research Group for Esophageal Cancer (CURE). Journal of Gastrointestinal Surgery 9(6): 794-802, 2005

Oral proton pump inhibitors are as effective as endoscopic treatment for bleeding peptic ulcer: a prospective, randomized, controlled trial. Digestive Diseases and Sciences 52(12): 3371-3376, 2007

Long-Term Outcomes of Endoscopic Resection for Early-Stage Esophageal Squamous Cell Neoplasms: a Multicenter Prospective Study. Gastrointestinal Endoscopy 79(5): Ab132-Ab133, 2014

A prospective randomized controlled trial demonstrating the effectiveness of an educational intervention in improving proton pump inhibitor dosing habits. Digestive Disease Week Abstracts & Itinerary Planner : Abstract No S1605, 2003

Clinical trial: rebamipide promotes gastric ulcer healing by proton pump inhibitor after endoscopic submucosal dissection--a randomized controlled study. Journal of Gastroenterology 45(3): 285-290, 2010